According to the Zhitong Finance App, Luxin Biotechnology (01084.HK) announced results for the six months ended June 30, 2026. The group's revenue for the period was 535 million yuan, an increase of 30.45% over the previous year. The owner of the company should have accounted for a loss of 1.392 million yuan, a year-on-year decrease of 88.47%; loss of 0.002 yuan per share.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.